tiprankstipranks
Trending News
More News >
Innovent Biologics (HK:1801)
:1801
Hong Kong Market

Innovent Biologics (1801) Income Statement

Compare
14 Followers

Innovent Biologics Income Statement

Last quarter (Q4 2024), Innovent Biologics's total revenue was ¥5.47B, an increase of 136.09% from the same quarter last year. In Q4, Innovent Biologics's net income was ¥297.99M. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 9.42B¥ 6.21B¥ 4.56B¥ 4.27B¥ 3.84B
Gross Profit
¥ 7.91B¥ 4.40B¥ 3.63B¥ 3.70B¥ 3.46B
Operating Expenses
¥ 7.65B¥ 5.07B¥ 6.21B¥ 6.05B¥ 3.50B
Depreciation and Amortization
¥ 275.60M¥ 385.10M¥ 319.42M¥ 204.75M¥ 85.63M
EBITDA
¥ -480.28M¥ -660.68M¥ -1.75B¥ -2.37B¥ -704.74M
Operating Income
¥ -755.87M¥ -1.68B¥ -2.07B¥ -3.11B¥ -820.14M
Other Income/Expenses
¥ 677.25M¥ 534.89M¥ -96.54M¥ 61.63M¥ -301.53M
Pretax Income
¥ -78.62M¥ -1.14B¥ -2.17B¥ -3.05B¥ -858.71M
Net Income
¥ -94.63M¥ -1.03B¥ -2.18B¥ -3.14B¥ -998.42M
Per Share Metrics
Basic EPS
¥ -0.06¥ -0.66¥ -1.46¥ -2.16¥ -0.74
Diluted EPS
¥ -0.06¥ -0.66¥ -1.46¥ -2.16¥ -0.74
Weighted Average Shares Outstanding
1.63B 1.56B 1.49B 1.45B 1.35B
Weighted Average Shares Outstanding (Diluted)
1.63B 1.56B 1.49B 1.46B 1.36B
Currency in CNY

Innovent Biologics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis